Literature DB >> 19933920

Predictors of competing mortality in advanced head and neck cancer.

Loren K Mell1, James J Dignam, Joseph K Salama, Ezra E W Cohen, Blase N Polite, Virag Dandekar, Amit D Bhate, Mary Ellyn Witt, Daniel J Haraf, Bharat B Mittal, Everett E Vokes, Ralph R Weichselbaum.   

Abstract

PURPOSE Death from noncancer causes (competing mortality) is an important event in head and neck cancer, but studies identifying predictors of this event are lacking. We sought to identify predictors of competing mortality and develop a risk stratification model for competing events. PATIENTS AND METHODS Cohort study of 479 patients with stage III to IV carcinoma of the head and neck diagnosed between August 1993 and November 2004. Patients were treated on consecutive prospective clinical trials involving organ-preserving chemoradiotherapy and surgery. We used multivariable competing risks regression models to analyze factors associated with the cumulative incidence of competing mortality, locoregional and distant failure, and second malignancies as first events. Results Median follow-up was 52 months median for survivors. The 5-year cumulative incidence of competing mortality was 19.6% (95% CI, 15.8 to 23.4). On multivariable analysis, competing mortality was associated with female sex (hazard ratio [HR], 1.72; 95% CI, 1.13 to 2.63), increasing age (HR, 1.30; 95% CI, 1.04 to 1.62), increasing Charlson Comorbidity Index (HR, 1.24; 95% CI, 1.05 to 1.47), decreasing body mass index (HR, 0.33; 95% CI, 0.13 to 0.84), and decreasing distance traveled to the treating center (HR, 0.65; 95% CI, 0.44 to 0.98). Patients with zero, one, two, and > or = three risk factors had 5-year competing mortality of 8.9% (95% CI, 3.0% to 14.8%), 12.4% (95% CI, 7.0% to 17.8%), 22.1% (95% CI, 14.5% to 29.7%), and 39.3% (95% CI, 28.6% to 50.1%), respectively. CONCLUSION Competing mortality in advanced head and neck cancer is associated with several demographic and health status characteristics. Analyses of risk factors for competing mortality may be useful in outcomes reporting and designing clinical trials.

Entities:  

Mesh:

Year:  2009        PMID: 19933920     DOI: 10.1200/JCO.2008.20.9288

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  41 in total

1.  Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence.

Authors:  Hyunsoon Cho; Angela B Mariotto; Bhupinder S Mann; Carrie N Klabunde; Eric J Feuer
Journal:  Am J Epidemiol       Date:  2013-07-03       Impact factor: 4.897

2.  Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer.

Authors:  Loren K Mell; Hanjie Shen; Phuc Felix Nguyen-Tân; David I Rosenthal; Kaveh Zakeri; Lucas K Vitzthum; Steven J Frank; Peter B Schiff; Andy M Trotti; James A Bonner; Christopher U Jones; Sue S Yom; Wade L Thorstad; Stuart J Wong; George Shenouda; John A Ridge; Qiang E Zhang; Quynh-Thu Le
Journal:  Clin Cancer Res       Date:  2019-08-16       Impact factor: 12.531

Review 3.  [Translational research in head and neck cancer. Biological characteristics and general aspects].

Authors:  A Dietz; G Wichmann
Journal:  HNO       Date:  2011-09       Impact factor: 1.284

4.  Challenges to delivery and effectiveness of adjuvant radiation therapy in elderly patients with node-positive vulvar cancer.

Authors:  Cameron W Swanick; Patricia J Eifel; Jinhai Huo; Larissa A Meyer; Grace L Smith
Journal:  Gynecol Oncol       Date:  2017-05-12       Impact factor: 5.482

5.  Competing causes of death in patients with oropharyngeal cancer treated with radiotherapy.

Authors:  Johnny Kao; K H Vincent Lau; Charles C L Tong; Chien-Ting Chen
Journal:  Exp Ther Med       Date:  2012-02-23       Impact factor: 2.447

6.  Is postoperative adjuvant chemoradiotherapy necessary for high-risk oropharyngeal squamous cell carcinoma?

Authors:  Tomoya Yokota; Tetsuro Onitsuka; Kimihide Kusafuka; Hirofumi Ogawa; Yusuke Onozawa; Masahiro Nakagawa; Yoshiyuki Iida; Tomoyuki Kamijo; Tetsuo Nishimura; Takashi Nakajima; Narikazu Boku; Hirofumi Yasui
Journal:  Int J Clin Oncol       Date:  2013-03-05       Impact factor: 3.402

7.  Competing mortality and fracture risk assessment.

Authors:  W D Leslie; L M Lix; X Wu
Journal:  Osteoporos Int       Date:  2012-06-27       Impact factor: 4.507

8.  Elderly patients with squamous cell carcinoma of the head and neck and the benefit of multimodality therapy.

Authors:  Virginia A Moye; Sindhu Chandramouleeswaran; Ni Zhao; Hyman B Muss; Mark C Weissler; David N Hayes; Jose P Zevallos
Journal:  Oncologist       Date:  2015-01-12

9.  Age-adjusted comorbidity and survival in locally advanced laryngeal cancer.

Authors:  Collin F Mulcahy; Abdallah S R Mohamed; Aasheesh Kanwar; Katherine A Hutcheson; Alokananda Ghosh; David Vock; Randal S Weber; Stephen Y Lai; Gary Brandon Gunn; Mark Zafereo; William H Morrison; Renata Ferrarotto; Adam S Garden; David I Rosenthal; Clifton D Fuller
Journal:  Head Neck       Date:  2018-05-13       Impact factor: 3.147

10.  Competing causes of death and medical comorbidities among patients with human papillomavirus-positive vs human papillomavirus-negative oropharyngeal carcinoma and impact on adherence to radiotherapy.

Authors:  Clayton B Hess; Dominique L Rash; Megan E Daly; D Gregory Farwell; John Bishop; Andrew T Vaughan; Machelle D Wilson; Allen M Chen
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-04       Impact factor: 6.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.